Moore RD - Search Results

1

Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts.

Schechter M, Zajdenverg R, Falco G, Barnes GL, Faulhaber JC, Coberly JS, Moore RD, Chaisson RE. Schechter M, et al. Among authors: moore rd. Am J Respir Crit Care Med. 2006 Apr 15;173(8):922-6. doi: 10.1164/rccm.200512-1953OC. Epub 2006 Feb 10. Am J Respir Crit Care Med. 2006. PMID: 16474028 Free PMC article. Clinical Trial.

2

Hepatitis C and progression of HIV disease.

Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Sulkowski MS, et al. Among authors: moore rd. JAMA. 2002 Jul 10;288(2):199-206. doi: 10.1001/jama.288.2.199. JAMA. 2002. PMID: 12095384

3

Initiation of highly active antiretroviral therapy at CD4+ T lymphocyte counts of >350 cells/mm3: disease progression, treatment durability, and drug toxicity.

Sterling TR, Chaisson RE, Moore RD. Sterling TR, et al. Among authors: moore rd. Clin Infect Dis. 2003 Mar 15;36(6):812-5. doi: 10.1086/367934. Epub 2003 Feb 27. Clin Infect Dis. 2003. PMID: 12627368

4

Survival in an urban HIV-1 clinic in the era of highly active antiretroviral therapy: a 5-year cohort study.

Lucas GM, Chaisson RE, Moore RD. Lucas GM, et al. Among authors: moore rd. J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):321-8. doi: 10.1097/00126334-200307010-00005. J Acquir Immune Defic Syndr. 2003. PMID: 12843742

5

The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons.

Mehta SH, Moore RD, Thomas DL, Chaisson RE, Sulkowski MS. Mehta SH, et al. Among authors: moore rd. J Acquir Immune Defic Syndr. 2003 Aug 15;33(5):577-84. doi: 10.1097/00126334-200308150-00005. J Acquir Immune Defic Syndr. 2003. PMID: 12902801

6

Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study.

Sterling TR, Chaisson RE, Keruly J, Moore RD. Sterling TR, et al. Among authors: moore rd. J Infect Dis. 2003 Dec 1;188(11):1659-65. doi: 10.1086/379741. Epub 2003 Nov 14. J Infect Dis. 2003. PMID: 14639536

7

Differences in HIV disease progression by injecting drug use in HIV-infected persons in care.

Moore RD, Keruly JC, Chaisson RE. Moore RD, et al. J Acquir Immune Defic Syndr. 2004 Jan 1;35(1):46-51. doi: 10.1097/00126334-200401010-00006. J Acquir Immune Defic Syndr. 2004. PMID: 14707791

8

Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy.

Karakousis PC, Moore RD, Chaisson RE. Karakousis PC, et al. Among authors: moore rd. Lancet Infect Dis. 2004 Sep;4(9):557-65. doi: 10.1016/S1473-3099(04)01130-2. Lancet Infect Dis. 2004. PMID: 15336223 Review.

9

Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir.

Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD. Sulkowski MS, et al. Among authors: moore rd. AIDS. 2004 Nov 19;18(17):2277-84. doi: 10.1097/00002030-200411190-00008. AIDS. 2004. PMID: 15577540

10

The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection.

Mehta SH, Thomas DL, Torbenson M, Brinkley S, Mirel L, Chaisson RE, Moore RD, Sulkowski MS. Mehta SH, et al. Among authors: moore rd. Hepatology. 2005 Jan;41(1):123-31. doi: 10.1002/hep.20541. Hepatology. 2005. PMID: 15619237

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

931 results

Search Page

Filters